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Abstract
Autophagy is an intracellular lysosomal degradative pathway important for tumor surveillance. Autophagy deficiency
can lead to tumorigenesis. Autophagy is also known to be important for the aggressive growth of tumors, yet the
mechanism that sustains the growth of autophagy-deficient tumors is not unclear. We previously reported that
progression of hepatic tumors developed in autophagy-deficient livers required high mobility group box 1 (HMGB1),
which was released from autophagy-deficient hepatocytes. In this study we examined the pathological features of the
hepatic tumors and the mechanism of HMGB1-mediated tumorigenesis. We found that in liver-specific autophagy-
deficient (Atg7ΔHep) mice the tumors cells were still deficient in autophagy and could also release HMGB1. Histological
analysis using cell-specific markers suggested that fibroblast and ductular cells were present only outside the tumor
whereas macrophages were present both inside and outside the tumor. Genetic deletion of Hmgb1 or one of its
receptors, receptor for advanced glycated end product (Rage), retarded liver tumor development. HMGB1 and RAGE
enhanced the proliferation capability of the autophagy-deficient hepatocytes and tumors. However, RAGE expression
was only found on ductual cells and Kupffer’s cells but not on hepatoctyes, suggesting that HMGB1 might promote
hepatic tumor growth through a paracrine mode, which altered the tumor microenvironment. Finally, RNAseq analysis
of the tumors indicated that HMGB1 induced a much broad changes in tumors. In particular, genes related to
mitochondrial structures or functions were enriched among those differentially expressed in tumors in the presence or
absence of HMGB1, revealing a potentially important role of mitochondria in sustaining the growth of autophagy-
deficient liver tumors via HMGB1 stimulation.
Introduction
Autophagy is an important mechanism regulating
tumorigenesis. Its dysfunction due to external stress or
genetic inactivation may lead to tumorigenesis. Indeed,
liver-specific deletion of Atg5 or Atg7 (Atg5ΔHep or
Atg7ΔHep) causes hepatic tumorigenesis1–4. Similarly,
reduced autophagic activity from constant activation of
mammalian target of rapamycin complex 1 (mTORC1)
also promotes hepatic neoplastic transformation5,6. These
studies suggest that hepatocytes require the tumor-
suppressive function of autophagy for maintaining its
homeostasis.
Excessive reactive oxygen species (ROS) generated due
to autophagy-deficiency is implicated in tumor develop-
ment7,8. Consequently, pharmacological inhibition of ROS
formation by the antioxidant N-acetylcysteine results in a
strong suppression of tumor development in Atg5-defi-
cient liver8. Moreover, there is a persistent activation of an
anti-oxidative stress-related transcription factor NRF2
(nuclear factor, erythroid 2 like 2) to limit the oxidative
injury9. Paradoxically, codeletion of Nrf2 gene also pre-
vents tumorigenesis in the autophagy-deficient liver1,3.
In additon, autophagy can regulates hepatic tumor-
igenesis by modulating the release of a damage-associated
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molecular pattern (DAMP) molecule, HMGB1. We have
shown that defective autophagy leads to NRF2-mediated
activation of Caspase-1/11, which in turn causes HMGB1
release2. It is known that extracellular HMGB1 acts as an
immune mediator in sterile inflammation. However,
codeletion of Hmgb1 in the autophagy-deficient liver
results in delayed tumor development via an unknown
mechanism independent of its usual role in inflammation
and fibrosis2.
In the present study, we have characterized the cellular
and molecular context of the hepatic tumors driven by
autophagy deficiency. We showed that HMGB1 and its
dominant receptor RAGE positively affect the prolifera-
tion of tumor cells, likely via a paracrine mode. RNA
sequencing analysis suggested that the effect of HMGB1
can affect the expressional level of multiple genes, parti-
cularly those involved in mitochondrial structure and
functions. Our data, therefore, identify a key role of
HMGB1 in promoting autophagy-deficient tumor growth
via novel mechanisms. HMGB1 could thus be a potential
therapeutic target.
Results
Hepatic tumor cells in autophagy-deficient livers had
features consistent with autophagy deficiency
Autophagy possesses both antitumorigenic and protu-
morigenic role, depending on whether it occurs before or
after the onset of tumorigenesis. Autophagy-deficient
livers develop tumors, confirming the surveillance role of
autophagy in the liver. The tumor first appears at the 9-
month of the age and the tumor size and the number
gradually increase as the mice get older2,3. The tumors in
the autophagy-deficient livers seem to be hepatic ade-
noma, which does not metastasize3. However, the mole-
cular and cellular nature of these tumors had not been
fully characterized.
Hepatic deletion of Atg7 caused defective formation of
LC3-II, an autophagy-specific marker, in tumor and non-
tumor liver tissue, when compared with age-matched
Atg7-floxed (Atg7 F/F) liver (Fig. 1a), indicating that the
tumors were also deficient in autophagy and that they
would have arisen from the autophagy-deficient hepato-
cytes. We confirmed this notion by examining the
expression of SQSTM1 and ubiquitin (UB) in the liver.
Immunohistological and immunofluorescence analysis
was performed by taking images of eight different regions
covering the non-tumor, peri-tumor, and the tumor
regions as shown in Fig. 1b. A clear accumulation of
SQSTM1 and UB in the tumor region of the autophagy-
deficient liver was observed, which was at the level similar
to that in the non-tumor tissues (Fig. 1c, d), suggesting
that the tumor tissues were defective in autophagy and
had defective protein quality control. In addition, the
tumor tissues were positive for the hepatocyte-specific
marker, HNF4α, which was colocalized in the same cells
that had elevated SQSTM1 and UB staining (Fig. 1f).
We next analyzed whether the accumulation of
SQSTM1 in tumor tissue could activate the anti-oxidative
response-related NRF2 transcription factor as in non-
tumor tissues1,9. We found that the protein and the
mRNA level of Nqo1 and Gstm1 (NRF2 target genes) were
drastically elevated in the tumor tissues of the Atg7ΔHep
mice (Fig. 1a, g). These observations indicated that
hepatic tumors in autophagy-deficient livers arise from
the autophagy-deficient hepatocytes with upregulated
NRF2 and SQSTM1 levels.
Hepatic progenitor cells were localized exclusively in the
non-tumor region but not inside the tumor
Hepatic progenitor cells (HPCs), also known as oval
cells or ductular cells, expand during chronic liver injury
in patients and in rodents10,11. The expansion of HPCs is
significant in the autophagy-deficient livers2. HPCs has
been noted to possess the capacity to become tumorigenic
in vivo12. We thus explored the relationship of these cells
to the tumor in autophagy-deficient livers by examining
their spatial interactions.
H-E staining showed that the distribution of HPCs was
mostly around the tumor-adjacent region (Fig. 2a). In the
area of tumor tissues, the normal tissue architecture, such
as bile duct, and portal tract formation, was completely
lost. Moreover, the tumor region was composed of irre-
gular hepatic plates with tumor cells showing large
nuclear-cytoplasmic ratio and occasionally nuclear atypia
(Fig. 2a). Immunostaining for CK19 and Sox9, common
markers for expanded HPCs, was negative in the tumor
(Fig. 2b, c). Instead, most of the CK19- or Sox9 positive
cells appear to form a compact sheet surrounding the
tumor (Fig. 2b, c). Some of the HPCs were positive for
SQSTM1 aggregates (Supplementary Fig. S1A–B). The
possibility that some of these SQSTM1 positive HPCs
may be derived from the autophagy-deficient hepatocytes
cannot be excluded as such transdifferentiation had been
reported previously10,13.
Interestingly, HPC and liver cancer stem cells (CSCs)
also share several cellular markers, such as EpCAM,
CD133 and CD2414,15. HPCs in the context of chronic
liver injury have also been considered as a possible origin
of liver CSCs. We thus analyzed the expression of these
CSC markers in the non-tumor and tumor tissues of the
autophagy-deficient liver. Real-time PCR analysis showed
that the expression of Cd133, Cd200, Cd34, Cd44, Ly6a/
Sca1 and Ly6d, but not Cd24a and Cd90, were sig-
nificantly upregulated in Atg7ΔHep livers compared with
control Atg7 F/F livers (Supplementary Fig. S2A). The
elevation of these CSC markers in the tumor tissues also
suggested that tumors had a precursor/stem-cell pheno-
type. Interestingly, most of the stemness-related
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Fig. 1 Hepatic tumor in autophagy-deficient livers are derived from autophagy-deficient hepatocytes. a Immunoblot analysis of autophagy
function-related proteins (ATG7, SQSTM1, LC3B-I/II) and NRF2 pathway-related proteins (NQO1) in whole livers isolated from 15-month-old Atg7F/F,
and Atg7ΔHep mice. b Schematic representation of the non-tumor, peri-tumor, and tumor region of the liver sections. Region 1 and Region 5: peri-
tumor region, Region 2-Region 4: tumor region, and Region 6- Region 8: non-tumor region. c–e Livers from 12-month-old mice of Atg7ΔHep genotype
were sectioned and immunostained with anti-SQSTM1(C), Anti-Ubiquitin (UB) (d), or anti-HNF4α (e). Dotted lines indicate the tumor border.
f Magnified image of the region 1(peri- and intra-tumor region) of (c–e). g The hepatic mRNA expression level of NRF2 target genes, Nqo1 and Gstm1,
in the livers of 15-month-old Atg7F/F, and in the non-tumor and tumor samples from the liver of age-matched Atg7ΔHep mice. NT, non-tumor, T,
tumor. Data are reported as mean ± SE, *P < 0.05; n= 3 mice per group.
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Fig. 2 Hepatic progenitor cells and fibrosis are localized exclusively in peri-tumor and non-tumor regions but are absent inside the tumor.
Liver sections from 12-month-old mice of the Atg7ΔHep genotype were subjected to H-E staining (a) (original magnification, ×200) and
immunostaining for CK19 (b), SOX9 (c), Desmin immunostaining (d), Sirius Red stain (e), or Trichrome stain (f) (original magnification, ×200). Dotted
lines indicate the tumor border. NT, non-tumor, T, tumor.
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transcription factors such as Oct4, Nanog, Klf4 and Sox2
were significantly downregulated in Atg7ΔHep livers
(Supplementary Fig. S2B). The lack of expression of
Nanog has been linked to the adenoma nature of the
tumor16. These changes were not more significant in the
tumor tissue than in the non-tumor tissues, and thus may
not be the mechanisms discriminating the two types of
tissues.
HPCs have been reported to express multiple angio-
genic paracrine factors such as vascular endothelial
growth factor (VEGF), platelets-derived growth factor
(PDGF), and angiopoietin (ANGPT) in pediatric hepato-
blastoma17. These HPCs could interact with pro-
tumorigenic cells heterotypically via mitogenic factors.
Indeed, real-time PCR analysis indicated that expression
of Angpt2 and Pdgfb, but not Vegfa and Angpt1, were
significantly upregulated in Atg7ΔHep tumor and non-
tumor livers, compared with wild-type Atg7 F/F mice
(Supplementary Fig. S3), suggesting the differential
involvement of angiogenic factors in the peritumoral
niche of Atg7ΔHep mice. Taken together, the distinct
separation of the HPCs and tumor cells in the Atg7ΔHep
livers suggests that HPCs may not evolve into the tumor
cells but could contribute to a tumor microenvironment
that affects tumorigenesis.
Fibrosis was present in the peri-tumor region and
encapsulated the tumor
Development of hepatic tumors are strongly associated
with fibrosis, with 80–90% of HCCs developing in the
fibrotic or cirrhotic livers18. On a cellular level, fibro-
genesis is most significantly mediated by the activation of
hepatic stellate cells (HSCs). Liver fibrosis occurs early in
the autophagy-deficient liver2. In the older tumor-bearing
Atg7ΔHep livers the number of desmin-expressing HSCs
was still at an elevated level (Fig. 2d). Unlike the dis-
tribution of macrophages, desmin-positive HSCs were
only present in the non-tumor and peri-tumor regions of
the liver, but not inside the tumor (Fig. 2d). Consistently,
increased fibrillar collagen deposition was only detected in
the non-tumor and peri-tumor region (Fig. 2e, f). Taken
together, the peri-tumoral desmin-positive HSCs may be
responsible for the production of the fibers that encap-
sulated and demarcated the tumor tissue. It is possible
that fibrosis in the autophagy-deficient liver may play an
inhibitory role against tumor infiltration into normal tis-
sues, thus contributing to the more benign presentation of
the tumorigenesis in this setting.
Macrophages but not other immune cells were found
inside the tumor
Hepatocellular neoplasia often occurs in the setting of
chronic inflammation, which is present in autophagy-
deficient livers2,19. Among many different types of
inflammatory cells, the tumor-associated macrophage
(TAM) are thought to contribute to the initiation and
promotion of tumors via cytokine factors. We thus
examined the distribution of hepatic F4/80-positive cells,
which showed their presence in both tumoral and non-
tumoral regions (Fig. 3a). In contrast, most of the mye-
loperoxidase (MPO)-positive neutrophils, CD3-positive
T cells, and CD45R-positive B cells were absent from the
tumoral region but present exclusively in the non-tumor
region (Fig. 3b–d). qRT-PCR analysis also found a strong
upregulation of F4/80 and Ly6c expression in 12-month-
old Atg7ΔHep livers as compared with age-matched Atg7F/
F livers, and there was a further elevation in tumor tissues
(Fig. 3f). The CD4 mRNA level was modestly elevated but
the CD8 mRNA level was significantly suppressed in the
tumor-bearing Atg7ΔHep liver (Fig. 3e).
Macrophages can play important roles in regulating
hepatocytes proliferation and survival by secreting
inflammatory cytokines, resulting in enhanced tumor
growth20. In contrast to the presence of infiltrating F4/
80-positive macrophages and the elevated expression of
F4/80 and Ly6c, the mRNA expression of TNFα, IL-6, Il-
1β, and IL-17 were paradoxically downregulated in the
tumor-bearing 12-month-old Atg7ΔHep livers (Supple-
mentary Fig. S4). These data suggest that there is
ongoing non-resolving inflammation in tumor and non-
tumor tissue of autophagy-deficient mice but their
contribution to tumor growth has yet to be fully deter-
mined. Alternatively other types of cytokines could be
involved.
Autophagy deficient hepatic tumor cells released HMGB1
Autophagy-deficient hepatocytes continuously release
HMGB1, which impacts the expansion of HPCs2. HMGB1
might recruit inflammatory cells or fibrotic cells to the
tumor region, promoting a permissive microenviron-
ment21,22. We thus sought to determine whether the
autophagy-deficient tumor tissues also release HMGB1,
which might result in a positive feedback enhancement.
We found that less HMGB1 proteins were present in
tumor and non-tumor tissue of the Atg7ΔHep liver, as
compared with the Atg7 F/F liver (Fig. 4a). Co-
immunofluorescence staining also showed that tumor
cells with accumulated SQSTM1 were also devoid of both
nuclear and cytosolic HMGB1 (Fig. 4b). The mRNA level
of HMGB1 was comparable between the liver tissues of
floxed and Atg7ΔHep mice (Fig. 4c). Thus, the results
indicated that autophagy-deficient tumor cells had
released HMGB1.
HMGB1 promoted hepatic proliferation
HMGB1 has a mitogenic effect in human HCC cell
lines23. HMGB1 released by autophagy-deficient hepato-
cytes affected the growth of tumorigenic hepatocytes2.
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Consistently, we now found that Atg7ΔHep livers had a
remarkably increased number of hepatocytes positive for
proliferation of cell nuclear antigen (PCNA) or Ki67,
which seemed to be present in both non-tumor and
tumor regions without much differences in the level (Fig.
5a) (Supplementary Fig. S5A, B). We then compared the
cellular proliferation in 15-month-old Atg7ΔHep and Atg7/
Hmgb1ΔHep mice to determine the role of HMGB1. Both
genotypes developed a notable but different number of
tumors at this age2. Immunostaining analysis for PCNA
showed a lower number of proliferating hepatocytes in the
tumor and non-tumor regions of Atg7/Hmgb1ΔHep livers
than those in the Atg7ΔHep livers (Fig. 5a), suggesting that
HMGB1 contributed to an overall enhanced proliferation
status in autophagy-deficient livers.
Further supporting this notion, we found that the
expression of Cyclin D1 was more significantly upregu-
lated in the tumor of Atg7ΔHep liver than in the tumors of
the Atg7/Hmgb1ΔHep livers (Fig. 5B, Supplementary Fig.
S6). Immunoblot analysis of Cyclin E also showed a higher
level in tumor and non-tumor regions of the Atg7ΔHep
livers than that in the Atg7/Hmgb1ΔHep livers (Fig. 5c, d).
Real-time PCR analysis demonstrated that hepatic
expression of CCND1, CCNA1, and CCNB1 were sig-
nificantly upregulated in Atg7ΔHep mice, compared with
Atg7 F/F mice (Fig. 5e). The expression of CCND1 and
CCNA1 was even more prominently elevated in the tumor
region than in the non-tumor tissues in Atg7ΔHep mice
(Fig. 5e). Such induction was not observed in tumor tis-
sues from Atg7/Hmgb1ΔHep mice (Fig. 5e), suggesting that
Fig. 3 Macrophages but not other immune cells are found within the tumor. Liver sections from 12-month-old mice of Atg7ΔHep genotype were
subjected to immunohistochemistry staining for F4/80 (a), Myeloperoxidase (MPO) (b), CD3 (c) and, CD45R (d) (original magnification, ×100). Dotted
lines indicate the tumor border. (e) The hepatic mRNA expression level of immune cell-associated genes in 15-month-old Atg7F/F and Atg7ΔHep liver
tissues. NT, non-tumor, T, tumor. Data are reported as mean ± SE, *P < 0.05, **P < 0.01, ***P < 0.001, n.s.: no significance; n= 3 mice per group.
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Hmgb1 deletion retarded cell cycle progression via the
downregulation of the expression of cyclins in the
autophagy-deficient livers. These results indicated that
hepatic tumors of Atg7/Hmgb1ΔHep were less proliferative
than the tumors in Atg7ΔHep mice. Thus HMGB1 had an
impact on cell proliferation in the autophagy-
deficient liver.
We then examined various cell growth relates signaling
pathways such as the PI3K/AKT pathway, the JNK path-
way, the mTORC1 pathway, the MAPK/ERK pathway,
and the JAK/STAT3 pathway, that regulates various cel-
lular responses in HCC proliferation and survival24–29.
Intriguingly, immunoblot analysis showed that phospho-
AKT and phospho-JNK was detected at higher levels in
Atg7/Hmgb1ΔHep livers compared with Atg7ΔHep livers
regardless the sample type (Supplementary Fig. S7A, B).
However, we did not detect significant differences in the
activation of other pathways related proteins between
Atg7ΔHep mice and Atg7/Hmgb1ΔHep mice (Supplementary
Fig. S7C–E). Taken together while the reason for the
paradoxical elevation of AKT and JNK phosphorylation in
Atg7/Hmgb1ΔHep livers is not clear these events do not
seem to be tumor specific and may not be related to the
reduced proliferation status of tumors from in these livers.
Alternativley, it is notable that hepatocytes could offer a
very different cellular context in which the conventional
oncogenes or tumor suppressor genes can act in opposite
ways30,31.
RAGE deletion impairs proliferation and retards liver tumor
development
Extracellular HMGB1 can binds to RAGE or TLR432. In
our previous study, Atg7ΔHep mice develop hepatic tumors
at 9-month old, which was inhbited by the deletion of
either Hmgb1 or Rage2. While Atg7/Hmgb1ΔHep at the age
of 12-month old were still largely devoid of tumors in the
liver2, we now found that 12-month-old Atg7ΔHep/Rage-/-
mice developed a significant presence of tumors (Fig. 6a),
which, however, were significantly smaller in size com-
pared with those in the Atg7ΔHep mice (Fig. 6b). Notably,
the number of PCNA-positive cells and the expression of
cyclin D1 were also remarkably decreased in Atg7ΔHep/
Rage-/- livers compared with that in the Atg7ΔHep livers
(Fig. 6c–d). These data suggest that the loss of Rage in
autophagy-deficient livers reduced tumor cell prolifera-
tion and tumor expansion in the liver. HMGB1 interac-
tion with the RAGE receptor can thus mediate a
significant level of cell proliferation and tumor develop-
ment in the autophagy-deficient liver.
To determine whether HMGB1 released by the
autophagy-deficient hepatocytes could act as an autocrine
or paracrine fashion to promote cellular proliferation, we
examined RAGE expression by immunofluorescence
staining in frozen tissue from Atg7 F/F and Atg7ΔHep livers.
We found that RAGE was almost exclusively expressed on
the surface of cells other than hepatocytes based on cell
morphology (Fig. 7a). Double immunofluorescence
Fig. 4 Hepatic HMGB1 is absent in the tumor of autophagy-deficient livers. a Livers of 15-month-old mice of different genotypes were
examined for HMGB1 by immunoblotting assay. b Liver sections from 15-month-old mice of different genotypes were immunostained with anti-
HMGB1 and anti-SQSTM1. White dotted lines indicate the tumor border. White arrowhead indicates the hepatocytes without nuclear HMGB1. c The
hepatic mRNA expression level of Hmgb1 in 15-month old-Atg7F/F and Atg7ΔHep mice, determined by real-time PCR. NT, non-tumor, T, tumor. Data
are reported as mean ± SE, n.s., no significance; n= 3 mice per group.
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showed that colocalization of RAGE was evident in CK19
or SOX9-positive ductular cells and F4/80-positive Kupf-
fer cells, but not on the Desmin-positive stellate cells in
Atg7ΔHep liver (Fig. 7b).
These findings indicate that RAGE was expressed on
ductular cells and Kupffer cells but not on hepatocytes
nor stellate cells. Futhermore, these observations suggest
that unlike the possible direct effect of HMGB1 on the
Fig. 5 Loss of HMGB1 in hepatocytes correlates with reduced proliferation in the tumor. a, b Liver sections from 15-month-old mice of
different genotypes were immunostained with anti-PCNA (a), or anti-Cyclin D (b). White arrow indicated proliferating hepatocytes. White dotted lines
indicate the tumor border. c Immunoblot analysis of PCNA, cyclin D1, and cyclin E proteins in the tumor or non-tumor sample of 15-month-old
Atg7ΔHep and, Atg7/Hmgb1ΔHep mice. d Densitometry qualification of the indicated proteins. e The hepatic mRNA level of indicated genes were
determined in the indicated tissues of 15-month-old mice of different genotypes, determined by real-time PCR. NT, non-tumor, T, tumor. Data are
reported as mean ± SE, *P < 0.05, **P < 0.01, n.s., no significance; n= 3 mice per group.
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expansion of CK19-positive or SOX9-positive ductual
cells2, the tumor-promoting effect of HMGB1 may not be
mediated by a direct effect on the autophagy-deficient
hepatocytes, but possibly by an indirect effect through
other RAGE-expressing cells, such as the Kupffer’s cells,
which could then alter the microenvironment to facilitate
tumor development.
RNA sequencing revealed key molecular differences
between tumors from Atg7ΔHep mice and from Atg7/
Hmgb1ΔHep mice
Since the effect of HMGB1 in promoting tumor devel-
opment may be at least in part mediated by an altered
microenvironment, there could be multiple alterations in
tumor behaviors affected by this process. We sought to
Fig. 6 Genetic loss of Rage inhibits tumorigenesis in autophagy-deficient livers. a Gross images of representative livers of 12-month-old Atg7ΔHep,
Atg7/Hmgb1ΔHep, Atg7ΔHepRage-/-, and Rage-/- mice. b Average number and size distribution of the tumors observed in the livers of 12-month-old mice
of different genotypes. c–d Liver sections from 12-month-old mice of different genotypes were immunostained with anti-PCNA (c), or anti-Cyclin D (d).
White dotted lines indicate the tumor border. NT. non-tumor, T, tumor. Data are reported as mean ± SE, *P < 0.05, **P < 0.01, ***P < 0.001, n.s., no
significance; n= 3 mice per group. Size information of the tumor from Atg7/Hmgb1ΔHep livers is derived from what we has previously reported2.
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investigate the transcriptomic profile of the tumor to
better understand the impact of HMGB1 on tumor
development in autophagy-deficient livers. We chose to
perform RNA sequencing on tumor tissues obtained from
Atg7ΔHep and Atg7/Hmgb1ΔHep mice at the age of 15-
months old, when the tumor number and size were
comparable in these mice.
The principal component analysis (PCA) on the RNA-
seq data indicated different transcriptomic profiles in the
tumor tissues of the two strains of mice when compared
with the non-tumor tissues (Fig. 8a), The six non-tumor
samples from the two strains of mice were close to each
other. In addition, two out of the three tumor samples
from Atg7/Hmgb1ΔHep livers were also close to the non-
tumor samples whereas tumor samples from Atg7ΔHep
mice were separated the farthest from the rest of the
samples. PCA thus suggests that tumors from the two
strains of mice were quite different with those from Atg7/
Hmgb1ΔHep livers more similar to the non-tumor tissues
in their transcriptomic profiles.
Differential expression analysis showed that 284 and
372 differentially expressed genes (DEGs) were upregu-
lated in tumors of Atg7ΔHep and Atg7/Hmgb1ΔHep livers,
respectively, whereas 326 and 300 genes were down-
regulated in tumors of these livers, respectively (Fig. 8b, c).
A complete list of these DEGs can be found in Supple-
mentary Tables S1–S5. We then focused on discovering
unique molecular features in the tumors associated with
the presence and absence of HMGB1. When comparing
the DEGs between Atg7ΔHep and Atg7/Hmgb1ΔHep
tumors, a small number of upregulated (28, Fig. 8b) or
downregulated (12, Fig. 8c) DEGs were found in tumor
tissues of both strains. The larger portions of DEGs were,
however, unique in Atg7ΔHep and in Atg7/Hmgb1ΔHep
tumors, supporting the notion that the tumors were dif-
ferent in the presence or absence of HMGB1.
To understand the molecular features of these differ-
ences, we determined the gene ontology (GO) terms and
KEGG pathways that were significantly enriched in the
unique DEG sets. We found that many biological pro-
cesses, particularly those associated with mitochondrial
structrures or functions were significantly over-
represented by the uniquely upregulated DEGs in
Atg7ΔHep tumors (Fig. 8d). Notably, DEGs that were
uniquely downregulated in Atg7/Hmgb1ΔHep tumors were
also enriched for those involved in the mitochondrial
structures or functions, (Fig. 8f). Many genes related to
mitochondrial oxidative phosphorylation (OXPHOS) or
electron transport chain (ETC) process were significantly
downregulated in the tumors of Atg7/Hmgb1ΔHep livers.
Fig. 7 RAGE is expressed by ductular cells and Kupffer’s cells but not by hepatocytes or stellate cells. a Immunofluorescence staining for
RAGE antigen in the livers of 9-week-old mice of Atg7F/F and Atg7ΔHepgenotype. Framed areas are enlarged and shown in separate panels (a, b).
b Liver sections from 9-week-old Atg7ΔHepmice were coimmunostained with anti-RAGE, together with anti-CK19 or SOX9 or F4/80 or Desmin. White
arrows indicate cells with colocalized signals.
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Fig. 8 RNAseq analysis indicates transcriptomic differences in the hepatic tumors of Atg7ΔHepmice and Atg7/Hmgb1ΔHep mice. a PCA of
transcriptomic data based on 12 RNA-seq samples under the four indicated combinations of genotypes and tissue types. b–c Numbers of DEGs that
are significantly upregulated (b) or downregulated (c) (p < 0.01) in the tumor samples of Atg7/Hmgb1ΔHep and/or Atg7ΔHepmice. The p-values are
indicated for the overlap between the two groups of upregulated or downregulated DEGs, respectively. d GO biological processes significantly over-
represented in the non-overlapped 256 DEGs uniquely elevated in the tumor samples of the Atg7ΔHep mice. e GO biological processes and KEGG
pathways significantly enriched in the non-overlapped 288 DEGs uniquely repressed in the tumor samples of the Atg7/Hmgb1ΔHep mice. For (d) and
(e), the heights of bars indicate the fold enrichment compared with random selection, whereas the red dots represent the statistical significance,
p-value after FDR-adjusted multiple test correction. The numbers in the bars represent the numbers of DEGs in the particular group which are
associated with corresponding GO terms. f Schematic model for the role of HMGB1 in tumor development in the autophagy-deficient liver. HMGB1 is
released from autophagy-deficient hepatocytes via the NRF2-inflammasome pathway. Deletion of RAGE, an HMGB1 receptor, mimicked the effect of
HMGB1 deletion in delaying tumor development, suggesting that HMGB1 affects tumor development via its released form, but not its DNA-binding
form. That HMGB1 may act on hepatocytes in an autocrine fashion could not be completely excluded although hepatocytes do not seem to express
a detectable level of RAGE. Released HMGB1 could thus have paracrine effects on target cells that express RAGE and may affect tumor development
by altering the microenvironment.
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Particulalry, the genes involved in the assembly or bio-
genesis of respiratory complex I (NADH dehydrogenase
complex) and complex III (Ubiquinol to Cytochrome c
electron transporter) were significantly downregulated.
These observations suggested that a major component of
the tumor-promoting effects of HMGB1 could be related
to mitochondrial function and activity, which may impact
the celluar bioenergetics and hence tumor growth in
autophagy-deficient liver.
Discussion
Autophagy is important for liver homeostasis and tumor
surveillance. Deficiency of hepatic autophagy leads to
tumor development in aged mice1–4. On the other hand,
autophagy function is required for the aggressive growth
of tumors. The mechanism that sustains the growth of
autophagy-deficient tumors is not known. Our findings
support the following conclusions: (1) The adenoma ori-
ginates from the autophagy-deficient hepatocytes; (2)
Hepatocyte-derived HMGB1 stimulates tumor cell pro-
liferation; (3) HMGB1 mediates the proliferative signal at
least in part via RAGE in a paracrine mode; and (4)
Tumors developed in the presence or absence of HMGB1
have significantly different transcriptomic profiles and
mitochondria function could be an important mechanistic
linker to tumor promotion.
1. HMGB1 may act in a paracrine model to stimulate
tumor growth
Histological analysis suggests that tumor cells were
originated from the autophagy-deficient hepatocytes. The
composition of the tumor appears to be different from the
non-tumor liver tissue. In comparison to non-tumor tis-
sues where different hepatic cells coexist, the tumor tissue
consists of mainly the tumor cells (HNF4α positive), and
some macrophages (Figs. 1–3) (Supplementary Table S6).
Fibrotic cells and ductular cells seem to be responsible for
the formation of a fibrous capsule that demarcates the
tumor from the non-tumor tissue. How the autophagy-
deficient hepatocytes form the adenomatous nodule,
excluding the fibrotic cells and ductular cells but retaining
some macrophages, is intriguing. But macrophages could
belong to those known as TAM and may enter into the
tumor tissue via tumor blood vessels33.
HMGB1 is known to promote tumor development2,34,35.
HMGB1 has been shown to be important for expansion of
ductular cells2,34, immune cells recruitment22 and activa-
tion of fibrotic cells21. All these cellular events could favor
tumorigenesis. We now know that non-tumorigenic2 and
tumorigenic (this study) autophagy-deficient hepatocytes
both can release HMGB1. The proliferative effect of
HMGB1 could be mediated via its receptor, RAGE (Fig. 6),
although deletion of Rage was not as effective as deletion of
Hmgb1 to deter tumor development2 (Fig. 6a, b). It is
possible that HMGB1 may affect the tumorigenesis process
through other receptors, such as TLR432. Future studies
can assess the potential role of TLR4 in this process.
At the cellular level, RAGE is not expressed by hepatocytes
and stellate cells at the detectable level by immunostaining.
But it could be readily detected on the surface of Kupffer’s cells
and HPCs2,36. Hence the effect of HMGB1 in cell proliferation
could be mediated by a paracrine manner, although the
autocrine mode could be not be completedly excluded
(Fig. 8f). In the paracrine mode, HMGB1 released by
hepatocytes could activate macrophages and/or ductular
cells, which may then promote an intratumoral micro-
environment favoring cell growth and proliferation.
However, it seems that some of the well-defined proin-
flammatory cytokines such as TNFα, IL-1β, and IL-6 may
not play the role as the expression of these cytokines were
remarkably downregulated in tumor tissues (Supple-
mentary Fig. S4). On the other hand, the RAGE-positive
peri-tumoral ductular cells could possibly communicate
with hepatocytes via cytokines such as angiogenic factors
ANGPT2 and PDGFβ to promote angiogenesis tumor
development. It is also possible that the protumorigenic
factors from TAM and/or ductular cells could be medi-
ated by other cytokines, chemokines, extracellular vesi-
cles, microRNAs or other cellular factors37.
2. The impact of HMGB1 on tumor cells can be broad
Deletion of Hmgb1 or Rage led to a signficant reduction
in the proliferative capability of autophagy-deficient
hepatocytes and tumors as demonstrated by the expres-
sion of PCNA, Ki67 and Cyclin D1. Thus the pro-
proliferative effect by HMGB1 confers a generally stron-
ger capability of proliferation to autophagy-deficient
hepaotcytes, which would be benefical to the growth of
tumors that are derived from these cells.
However, RNAseq analysis indicates that there are
much more unique changes in the molecular composition
of the tumors affected by HMGB1. The enrichment of
certain gene expression related to mitochondrial structure
and function in the presence of HMGB1 and lack of such
enrichment in the absence of HMGB1 are quite sig-
nificant. Hmgb1 deletion appears to suppress the mito-
chondrial ETC in tumors of autophagy-deficient livers.
Whether and how downregulation of genes of mito-
chondrial ETC may suppress cell proliferation in Atg7/
Hmgb1ΔHep tumors is unclear. But it is well known that
mitochondrial ETC enables many metabolic processes
and is a major sources of ATP and building blocks for
cellular activity. As a consequence of ETC dysfunction,
cell proliferation could be impaired due to bioenergetics
deficit. This notion is supported by the observation where
pharmacological or genetic inhibition of ETC caused
impaired cell proliferation of cells in vitro38,39. Interest-
ingly, a recent study suggest that ETC enables aspartate
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biosynthesis, a key proteogenic amino acid that is also a
precursor in purine and pyrimide synthesis and is
required for tumor growth and survival40,41. Thus tumors
in Atg7/Hmgb1ΔHep liver may have defective ETC that
could impair cell proliferation by limiting an intracellular
aspartate level besides having bioenergetics deficits. Many
metabolic pathways including glycolysis, the TCA cycle,
and β-oxidation produce the electron donors that fuel the
ETC. Hence, impairment or downregulation of ETC could
limit the regeneration of reducing equivalents, such as
NAD+, which in turn suppresses glycolysis or the TCA
cycle. Future studies should address these possibilities for
the understanding of how HMGB1 sustains the growth of
autoaphgy-deficient hepatic tumors.
In conclusion, our findings demonstrate that hepatic
adenoma originates from the autophagy-deficient hepa-
tocytes that release HMGB1. HMGB1, in turn, can sti-
mulate hepatocyte proliferation and hepatic tumorigenesis
via RAGE in the autophagy-deficient liver. The effect of
HMGB1 on tumor cells are broad as revealed by tran-
scriptomic analysis, which offers mechanistic clues for
future studies.
Materials and methods
Animal experiments
Atg7F/F, Atg7ΔHep, Atg7/Hmgb1ΔHep, Atg7ΔHepRage-/-,
Hmgb1-/-, and Rage-/- mice were used in this study.
Atg7F/F was obtained from Dr. Komatsu Masaaki (Nigata
University, Japan). These mice were backcrossed with
C57BL/6J for another 10 generations as described pre-
viously2,19. Albumin-Cre mice were obtained from the
Jackson Laboratory(Bar Harbor, ME). Hmgb1 F/F and
Rage mice were as described2. Atg7ΔHepmice were further
crossed with Hmgb1 F/F or Rage to generate Atg7/
Hmgb1ΔHepor Atg7ΔHep/Rage-/- mice as previously
described2. Both male and female mice were used in the
study. All animals received humane care, and all proce-
dures were approved by the Institutional Animal Care and
use Committee (IACUC) of the Indiana University.
Tumor sample collection
The whole liver was carefully removed from the eutha-
nized animals, washed, and placed in cold PBS. The number
of tumor nodules on the liver surface was counted for all
the liver lobes. Tumor nodules with >2mm in diameter
were carefully removed and examined as tumor tissue.
Tissue without visible tumor nodules were sampled as non-
tumor tissues. All tissues were collected in separate tubes
and stored at −80 oC for future studies. Liver tissues con-
taining the tumor nodule and the surrounding non-tumor
tissue were excised and fixed in 10% neutral formalin or
buffered with 4% PFA overnight for paraffin-embedding or
for OCT embedding. The tissue section was prepared from
the frozen or paraffin blocks for general histology, immu-
nostaining, and immunohistochemistry analysis.
General histological and immunological analysis
General histology was examined on paraffin-embedded
sections stained with hematoxylin and eosin (H-E). Liver
fibrosis was determined by Sirius Red staining or Mas-
son’s Trichome staining. For immunostaining, liver sec-
tions were subjected to heat-induced antigen retrieval
using citrate buffer (pH 6.0) followed by permeabilization
and blockage with 10% goat or donkey serum in PBS
containing 0.5% triton-X for 1 h. Sections were incubated
overnight at 4 oC with primary antibody diluted in PBS.
Primary antibodies used in this study are listed in Sup-
plementary Table S8. Sections were then incubated with
Alexa-488 or Cy3-conjugated secondary antibodies. Ima-
ges were obtained using Nikon Eclipse TE 200 epi-
immunofluorescence microscope. Hoechst 33342 was
used for nucleus staining. Images were analyzed using
NIS-element AR3.2 software.
Immunoblot analysis was performed as described pre-
viouosly2,19 using primary antibodies and respective sec-
ondary antibodies conjugated with horseradish peroxidase
as listed in Supplementary Table S8. The respective protein
bands were visualized using the immunobilion chemilu-
minescence system (Millipore, MA). The densitometry
analysis of immunoblotting images was performed using
Quantity One Software (Bio-rad). Densitometry values
were normalized to the loading control (GAPDH) and then
converted to units relative to the untreated control.
Total RNA isolation, reverse transcription, and quantitative
real-time PCR analysis
Total RNA was isolated from liver tissues using a
GeneTET RNA Purification Kit (Thermo Fisher Scien-
tific) according to the manufacturer’s protocol. cDNA was
synthesized using an M-MLV Reverse Transcriptase
Enzyme System (Life Technologies, Thermo Fisher Sci-
entific) and OligodT primers. The resulting cDNA pro-
ducts were subjected to qPCR reaction using SYBR Green
Master Mixes. qPCR was performed on a Quanta studio 3
PCR machine (Life Technologies–Applied Biosystems,
Thermo Fisher Scientific). The threshold crossing value
(Ct) was determined for each transcript and then nor-
malized to that of the internal gene transcript(β-actin).
Fold change values were then calculated using the 2–ΔΔCt
method. Genes-specific primers were designed using
Integrated DNA Technologies (IDT) PrimerQuest soft-
ware. Sequences of the forward and reverse primers are
listed in Supplementary Table S7.
RNA-sequencing and bioinformatics analysis
RNA was isolated as described above. RNAseq was
performed by The Center for Medical Genomics facility at
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Indiana University. The integrity of RNA was determined
using an Agilent Bioanalyzer 2100 (Agilent Technologies;
Santa Clara, CA). Extracted RNA was processed for rRNA
removal using the Epicenter rRNA depletion kit according
to the manufacturer’s instructions. rRNA-depleted RNA
was subsequently used to generate paired-end sequencing
libraries using the Illumina RNA TruSeq Library Kit
according to the manufacturer’s instruction. RNAseq was
performed using Illumina HiSeq 4000 (Illumina,
San Diego, CA). For bioinformatics analysis, we first
used FastQC (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc) to examine RNA-seq quality. Then all high-
quality sequences were mapped to the mouse genome
(mm10, UCSC Genome Browser, https://genome.ucsc.edu/)
with the STAR, an RNA-seq aligner42. The featureCounts
was adopted to assign uniquely mapped reads to genes
according to UCSC refGene (mm10)43. Those low-
expressed genes were not further analyzed if their raw
counts were less than 10 in more than three samples for
each pairwise comparison. The gene expression was nor-
malized cross all samples based on trimmed mean of M
(TMM) values implemented in EdgeR44, followed by dif-
ferential expression analysis given comparisons between
non-tumor and tumor tissues, in either single knockout or
double knockout mice. Genes with p values < 0.01 after
multiple-test false discovery rate (FDR) correction were
determined as DEGs for specific comparisons. The GO and
KEGG pathways significantly enriched in DEGs were
identified by DAVID functional annotation analysis tools45.
Statistical analysis
Statistical analyses were performed with Sigma Plot. All
experimental data were expressed as Mean ± SE. Student
t-test was performed to compare values from two groups.
To compare values obtained from three or more groups,
one-way ANOVA analysis with the appropriate post-hoc
analysis was used. Statistical significance was taken at the
level of P < 0.05.
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